Edition:
United States

Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

33.43USD
22 Jul 2016
Change (% chg)

$-0.02 (-0.06%)
Prev Close
$33.45
Open
$33.66
Day's High
$33.88
Day's Low
$32.95
Volume
213,627
Avg. Vol
363,543
52-wk High
$50.86
52-wk Low
$20.00

XLRN.O

Chart for XLRN.O

About

Acceleron Pharma Inc. is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic... (more)

Overall

Beta: --
Market Cap(Mil.): $1,244.29
Shares Outstanding(Mil.): 37.22
Dividend: --
Yield (%): --

Financials

  XLRN.O Industry Sector
P/E (TTM): -- 39.80 37.05
EPS (TTM): -1.33 -- --
ROI: -20.11 -5.86 14.35
ROE: -21.80 -4.70 15.56

BRIEF-Acceleron announces ACE-083 phase 1 results

* Announces ACE-083 phase 1 results at 14th International Congress On Neuromuscular Diseases

Jul 08 2016

BRIEF-Acceleron, Celgene says data with Luspatercept show increases in hemoglobin levels

* Acceleron and Celgene announce updated results from an ongoing Phase 2 study of Luspatercept in beta-thalassemia presented at the 21st congress of the European Hematology Association

Jun 10 2016

BRIEF-Acceleron Pharma Q1 loss per share $0.13

* Acceleron Pharma reports first quarter 2016 financial and operational results

May 05 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Ford Investor Services, Inc.
$12.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.